Benjamin L. Palleiko - 11 Aug 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Benjamin L. Palleiko
Issuer symbol
KALV
Transactions as of
11 Aug 2025
Net transactions value
$0
Form type
4
Filing time
13 Aug 2025, 17:29:45 UTC
Previous filing
10 Jul 2025
Next filing
19 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Palleiko Benjamin L CHIEF EXECUTIVE OFFICER, Director C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE /s/ Benjamin L. Palleiko 13 Aug 2025 0001366244

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Award $0 +113,920 $0.000000 113,920 11 Aug 2025 Common Stock 113,920 Direct F1, F2
transaction KALV Employee Stock Option Award $0 +113,920 $0.000000 113,920 11 Aug 2025 Common Stock 113,920 $12.51 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 11, 2025, subject to continued service through each vesting date.
F3 The option vests over a 4 year period: 1/48th on September 11, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.